Stem cell advocates are betting that the FDA’s recent openness toward peptides can help their industry break through. Chuck Meeker, a stem cell entrepreneur, told STAT at PepMed 2026, a conference for regenerative health businesses held by the American Academy of Peptide Medicine, that he expects the FDA to host public roundtables soon.
“I would say before the end of the year we have a series of FDA roundtables happening,” Meeker said. The FDA declined to say whether such events were imminent.
The Comparison Between Peptides and Stem Cells
Peptides and stem cells are both part of regenerative medicine, which aims to trigger the body’s natural healing processes. But while compounded peptides are having a moment with the FDA, commercially available, unapproved stem cell therapies have stayed a black sheep for the agency. Meeker and others at PepMed told STAT they believe that is about to change.
The comparison between the two fields is explicit. Peptides and stem cells are two peas in the pod of regenerative medicine. Both aim to activate the body’s innate capacity to heal itself.
Meeker’s Prediction on FDA Roundtables
Meeker’s prediction rests on the idea that the FDA’s willingness to engage with peptides signals a shift in how the agency treats regenerative medicine broadly. He framed the timing as a matter of months, not years.
The FDA’s tentative embrace of peptides is being read as a green light for stem cells. The industry sees the agency’s openness toward one category of therapy as a way to get a foot in the door for the other. The comparison between the two fields is not accidental.
What the Grey Market Means
Unapproved stem cell therapies have operated in a legal grey area for years. The industry wants to move those therapies from the grey market to mainstream acceptance.
The push to bring stem cells into the open is partly about legitimacy. Advocates want the FDA to regulate the field, which would mean accepting some level of oversight over therapies that have historically flown under the radar. The argument is that regulated access is better than no access at all.
The FDA’s Recent Engagement With Peptides
The FDA’s recent engagement with peptides suggests a shift in attitude. That engagement is what Meeker and others at PepMed are reading as a sign that the door is opening.
What the Industry Is Asking For
The stem cell industry is not asking for blanket approval. It is asking for a seat at the table. The roundtable format would allow advocates to present their case directly to regulators, making the argument for why stem cell therapies deserve more attention.
The FDA has not committed to hosting any roundtables on stem cells. The agency declined to say whether such events were imminent, leaving the question open. But the industry is confident that the FDA’s pattern on peptides suggests a similar path forward for stem cells.
The Risk of Moving Too Fast
The grey market for stem cells has been a concern for regulators. Unapproved therapies raise questions about safety and efficacy, and the FDA has signaled caution in the past. The industry’s argument is that bringing these therapies into the open would address that concern.
But the FDA has not moved quickly on stem cells. The agency has been slow to approve new products, and the industry has pushed back against that pace. The question now is whether the FDA’s engagement with peptides signals a broader shift in how it approaches the field.
What the Advocates Want From the FDA
The advocates at PepMed are making a specific ask. They want the FDA to host roundtables on stem cells, similar to the ones the agency has held on peptides. The format would allow them to present their case directly to regulators, making the argument for why stem cell therapies deserve more attention.
The FDA’s engagement with peptides is recent and still developing, and there is no guarantee that the same pattern will apply to stem cells. But the industry is operating on hope rather than certainty.
The Road Ahead
Meeker’s prediction is a bet on the FDA’s behavior. If the agency holds roundtables on peptides, the industry believes it will hold them on stem cells too. The timing is tight: Meeker expects roundtables before the end of the year.
Whether the FDA follows through is an open question. The agency has not committed, and the industry is operating on hope rather than certainty. But the advocates are convinced that the FDA’s engagement with peptides is a sign of things to come.
What We Make of It
The industry’s argument is straightforward: if the FDA is willing to engage with peptides, it will be willing to engage with stem cells. The comparison between the two fields is a useful framing, but it also carries risk. The FDA’s engagement with peptides is recent and still developing, and there is no guarantee that the same pattern will apply to stem cells.
The advocates are playing a long game. They are positioning themselves to be ready if the FDA decides to hold roundtables on stem cells. The question is whether the FDA will take that step, and whether the industry can convince regulators that stem cell therapies deserve the same kind of engagement as peptides.
The industry’s position is clear: stem cells are the next frontier in regenerative medicine, and the FDA’s engagement with peptides is proof that the agency is ready to engage with the field. Whether that proves true remains to be seen.
- Compounded peptides are having a moment with the FDA
- Commercially available, unapproved stem cell therapies remain a black sheep for the agency
- The industry sees the FDA’s embrace of peptides as a signal that stem cells could follow
- Meeker expects FDA roundtables on stem cells before the end of the year
- The FDA declined to confirm whether such events are imminent
Source material: “STAT+: Are stem cells the next peptides? These advocates think RFK Jr. could make it happen,” STAT.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.